Results from subanalyses of RATIONALE-303 and -304 add to the growing body of data on tislelizumab as a potential treatment for non-small cell lung cancer Biomarker studies shed light on ...
Tislelizumab is now approved in six indications in China This marks tislelizumab’s third approved lung cancer indication in China and first in a previously treated patient population The approval was ...
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BeiGene (NASDAQ:BGNE; HKEX:06160), a global science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced ...
Copyright © 2015 - 2021 Lifecarenews.in
